company background image
NTLA logo

Intellia Therapeutics NasdaqGM:NTLA Stock Report

Last Price

US$13.56

Market Cap

US$1.4b

7D

-0.7%

1Y

-57.4%

Updated

12 Dec, 2024

Data

Company Financials +

Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.4b

Intellia Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Intellia Therapeutics
Historical stock prices
Current Share PriceUS$13.56
52 Week HighUS$34.87
52 Week LowUS$12.82
Beta1.78
1 Month Change-18.56%
3 Month Change-38.56%
1 Year Change-57.44%
3 Year Change-88.17%
5 Year Change-12.49%
Change since IPO-38.64%

Recent News & Updates

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Nov 19

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

Nov 11

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Nov 05

Recent updates

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Nov 19

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

Nov 11

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Nov 05

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

Oct 25

Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case

Sep 25

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Sep 07
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)

Aug 03

Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Jun 06
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year

Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Jun 05

Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

May 14
Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

May 13

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01
Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Aug 06
Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Aug 04

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Jul 28

Intellia Therapeutics: Several Catalysts Expected For H2 2022

May 12

Intellia: One Patent Ruling Turns The Industry Upside Down

Mar 09

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Feb 25

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09
Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31
We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Shareholder Returns

NTLAUS BiotechsUS Market
7D-0.7%-2.7%-0.4%
1Y-57.4%3.3%27.7%

Return vs Industry: NTLA underperformed the US Biotechs industry which returned 3.3% over the past year.

Return vs Market: NTLA underperformed the US Market which returned 27.7% over the past year.

Price Volatility

Is NTLA's price volatile compared to industry and market?
NTLA volatility
NTLA Average Weekly Movement10.3%
Biotechs Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: NTLA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: NTLA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014526John Leonardwww.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.

Intellia Therapeutics, Inc. Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
NTLA fundamental statistics
Market capUS$1.44b
Earnings (TTM)-US$522.28m
Revenue (TTM)US$43.09m

32.1x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NTLA income statement (TTM)
RevenueUS$43.09m
Cost of RevenueUS$458.42m
Gross Profit-US$415.33m
Other ExpensesUS$106.96m
Earnings-US$522.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.13
Gross Margin-963.95%
Net Profit Margin-1,212.19%
Debt/Equity Ratio0%

How did NTLA perform over the long term?

See historical performance and comparison